Get the Stockscreener App
4.035
0.50%
0.015
Tvardi Therapeutics Inc stock is traded at $4.035, with a volume of 73,972.
It is up +0.50% in the last 24 hours and up +13.80% over the past month.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
See More
Previous Close:
$4.02
Open:
$3.92
24h Volume:
73,972
Relative Volume:
0.82
Market Cap:
$37.95M
Revenue:
$4.02M
Net Income/Loss:
$-13.95M
P/E Ratio:
-0.4095
EPS:
-9.8523
Net Cash Flow:
$-21.86M
1W Performance:
-0.25%
1M Performance:
+13.80%
6M Performance:
-87.01%
1Y Performance:
+0.00%
1-Day Range:
$3.92
$4.10
1-Week Range:
$3.80
$4.22
52-Week Range:
$3.50
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.045 | 37.71M | 4.02M | -13.95M | -21.86M | -9.8523 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.36 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.71 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-14-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Oct-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Brokerages - Defense World
Growth Report: Is Tvardi Therapeutics Inc attractive for institutional investorsInsider Selling & Entry Point Confirmation Alerts - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | 0HTC | US1407553072 - marketscreener.com
CARA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Free cash flow per share of Tvardi Therapeutics Inc. – FWB:69C - TradingView
Tvardi Therapeutics, Inc. (TVRD): Investor Outlook on the Biotech Company’s 125% Potential Upside - DirectorsTalk Interviews
MSN Money - MSN
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: Exploring a Potential 140% Upside in Biotechnology - DirectorsTalk Interviews
Will Tvardi Therapeutics Inc. (69C) stock sustain uptrend momentumTrade Performance Summary & Risk Managed Investment Entry Signals - mfd.ru
Will Tvardi Therapeutics Inc. outperform during market ralliesJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What is Tvardi Therapeutics Inc.’s book value per shareJuly 2025 Macro Moves & Long-Term Growth Plans - mfd.ru
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Look at the 129% Potential Upside in Biotech - DirectorsTalk Interviews
Published on: 2026-02-12 23:10:23 - mfd.ru
Will Tvardi Therapeutics Inc. stock maintain dividend yield2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate - Yahoo Finance
Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen - Defense World
Risk Report: Is BRLSW affected by consumer sentimentWeekly Gains Summary & Verified Entry Point Detection - baoquankhu1.vn
Tvardi Therapeutics (NASDAQ:TVRD) Raised to Strong-Buy at Lucid Cap Mkts - Defense World
Lucid Capital Markets upgrades Tvardi Therapeutics stock to Buy on valuation - Investing.com Nigeria
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital - TipRanks
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
Growth Report: Can Tvardi Therapeutics Inc sustain its profitabilityJuly 2025 Final Week & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
What is the long term forecast for Tvardi Therapeutics Inc. stockWeekly Stock Analysis & Capital Efficient Trade Techniques - mfd.ru
MACD Signal: What is the cash position of BEEPJuly 2025 Drop Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans? - simplywall.st
Tvardi Therapeutics (NASDAQ:TVRD) Lowered to Sell Rating by Wall Street Zen - Defense World
Tvardi Therapeutics, Inc. (TVRD) Investor Outlook: Exploring an 84% Potential Upside in Innovative Biotech - DirectorsTalk Interviews
Quarterly Earnings: What hedge funds are buying Tvardi Therapeutics Inc2025 Support & Resistance & Verified Short-Term Plans - baoquankhu1.vn
New Highs: How correlated is Tvardi Therapeutics Inc to the S P500July 2025 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn
Tvardi Therapeutics, Inc. Updates on Clinical Trials and Pipeline Progress - TradingView
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of “Hold” by Brokerages - Defense World
Why retail investors favor Tvardi Therapeutics Inc. stockQuarterly Growth Report & Low Volatility Stock Suggestions - Улправда
Will Tvardi Therapeutics Inc. (69C) stock gain from green policies2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Tvardi reports improved fibrosis scores with TTI-101 in IPF trial - Investing.com Nigeria
Will Tvardi Therapeutics Inc. stock split attract more investorsWeekly Gains Summary & Technical Buy Zone Confirmation - Улправда
Can Tvardi Therapeutics Inc. stock outperform in 2025 bull market2025 Support & Resistance & Low Volatility Stock Suggestions - Улправда
Will Tvardi Therapeutics Inc. stock recover faster than peersPortfolio Performance Report & Free Technical Confirmation Trade Alerts - Улправда
Can Tvardi Therapeutics Inc. (69C) stock stage a strong rebound this quarterWeekly Investment Report & Weekly High Return Forecasts - Улправда
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Risk Analysis: Will Tvardi Therapeutics Inc. stock split attract more investorsInflation Watch & Real-Time Stock Movement Alerts - Улправда
Why Tvardi Therapeutics Inc stock is seen as undervaluedWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - moha.gov.vn
Tvardi Therapeutics TTI-101 shows 9.4% fibrosis score decrease versus 2.4% placebo - marketscreener.com
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights - The Manila Times
Street Watch: Can Tvardi Therapeutics Inc stock outperform in 2025 bull marketWeekly Risk Report & Safe Capital Investment Plans - Bộ Nội Vụ
Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen - Defense World
Will Q4 Earnings Be a Catalyst for Cubex Tubings LimitedEconomic Data Impact & Free Hedging Tactics for Volatile Markets - earlytimes.in
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? - MSN
Tvardi Therapeutics, Inc. (TVRD) Total Expenses (TTM) - Zacks Investment Research
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):